Evidence map›Paper›PMID 42529245›Full record

ArticleJTO clinical and research reports2026

Biomarker Testing Among Patients With Nonsquamous NSCLC Across Three Time Periods and Three Testing Platforms-A Brief Report.

Zhen Jason Fan, Roxana Tudor, Michael Cabanero, Lisa W Le, Mary Rabey, Jennifer H Law, Tracey Stockley, Shelley Kuang, Nicholas Meti, Andreas Fung and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Zhen Jason FanDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Roxana TudorDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Michael CabaneroDepartment of Pathology, Laboratory Medicine Program, University of Toronto, Toronto, Canada.
Lisa W LeDepartment of Biostatistics, University Health Network, Toronto, Canada.
Mary RabeyDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Jennifer H LawDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Tracey StockleyDepartment of Pathology, Laboratory Medicine Program, University of Toronto, Toronto, Canada.
Shelley KuangDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Nicholas MetiDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Andreas FungDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Kirstin PerdrizetDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Kaitlin ChenDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Janice J N LiDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Noor GhummanDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Laura RanichDepartment of Pathology, Laboratory Medicine Program, University of Toronto, Toronto, Canada.
Cuihong WeiDepartment of Pathology, Laboratory Medicine Program, University of Toronto, Toronto, Canada.
Peter SabatiniDepartment of Pathology, Laboratory Medicine Program, University of Toronto, Toronto, Canada.
Prodipto PalDepartment of Pathology, Laboratory Medicine Program, University of Toronto, Toronto, Canada.
Ying-Han R HsuDepartment of Pathology, Laboratory Medicine Program, University of Toronto, Toronto, Canada.
Hyang Mi KoDepartment of Pathology, Laboratory Medicine Program, University of Toronto, Toronto, Canada.
Joerg SchwockDepartment of Pathology, Laboratory Medicine Program, University of Toronto, Toronto, Canada.
Ming S TsaoDepartment of Pathology, Laboratory Medicine Program, University of Toronto, Toronto, Canada.
Geoffrey LiuDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Frances A ShepherdDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Penelope BradburyDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Adrian SacherDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Lawson EngDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.
Natasha B LeighlDivision of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomarker testing in stage III/IV nonsquamous NSCLC is critical in treatment decision-making. This ambispective review included 1028 patients across three time periods to evaluate the clinical impact of evolving genomic testing platforms. Cohort 1 (C1: 2015-2017) had reflex EGFR/ALK testing. Cohort 2 (C2: 2017-2020) used limited next-generation sequencing (NGS; 15 genes), ALK, and ROS1 testing. Cohort 3 (C3: 2020-2022) used comprehensive NGS (161 genes). Larger NGS panels identified more actionable genomic alterations, but increased biopsy-to-result turnaround times and fewer patients had complete molecular results at first medical oncology consultation leading to delays in treatment initiation.

Indexed as

BiomarkersNSCLCPrecision medicineTurnaround time

Identifiers

PMID42529245
PMCPMC13416823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.